Chinese Innovative Drug Developer Haisco Pharmaceutical Group (SHE: 002653) Entered Wednesday August 26, 2026 an Exclusive Licensing Agreement With Sentivera, a Newly Formed US Venture Backed by Population Health Partners and ARCH Venture Partners, Extending the Growing Chinese Biotech Pattern of Ex-China Commercialization Partnerships Alongside Hengrui-Kailera (Ribupatide Triple Agonist Peptide, Global Phase 3 H1 2027), Hanmi-Genentech (HM17321 UCN2 Analog Peptide for Obesity, $190M Upfront + $2.3B Milestones, Announced August 24), and Innovent Biologics' Expanding US IND Activity (IBI3032 FDA IND Clearance August 5); Financial Terms and Specific Asset Details for the Haisco-Sentivera Agreement Have Not Been Fully Publicly Disclosed
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide, with Kailera's US Phase 3 planned H1 2027); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.